Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Data as of , from SEC Form 4 filings.
Net insider selling (90d)Watch CRBP
See up to 3 months of CRBP. The 7-day demo opens the 1M and 3M ranges and puts CRBP on your watchlist.
Start 7-day demoLatest CRBP insider trades
About Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Corbus Pharmaceuticals Holdings, Inc. is an SEC registrant, filing under CIK 0001595097, classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
CRBP Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 1 | 2,600 | $25K |
| Open-market sale | 3 | 31,000 | $308K |
| Grant or award | 2 | 250,009 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
CRBP insider transactions (Form 4)
5129 Form 4 filings on record, the earliest from Oct 21, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Yong Ben - Director | Open-market sale | Common Stock, par value $0.0001 per share | 2,000 | $7.84 footnote F2 | $16K | |
| ||||||
| Leonardo Viana Nicacio - Officer | Grant or award | Common Stock, par value $0.0001 per share | 58,333 footnote F1 | $0.00 | - | |
| Leonardo Viana Nicacio - Officer | Grant or award | Stock options (right to buy) | 191,676 | $0.00 | - | |
| ||||||
| Nishant C. Saxena - Officer | Open-market purchase | Common Stock, par value $0.0001 per share | 2,600 | $9.63 | $25K | |
| Yuval Cohen - Officer | Open-market sale | Common Stock, par value $0.0001 per share | 17,000 | $10.08 footnote F2 | $171K | |
| ||||||
| Sean F. Moran - Officer | Open-market sale | Common Stock, par value $0.0001 per share | 12,000 | $10.08 footnote F2 | $121K | |
| ||||||
| Winston Kung | Open-market sale | Common Stock, par value $0.0001 per share | 2,026 | $7.91 footnote F2 | $16K | |
| ||||||
| Anne Altmeyer | Open-market sale | Common Stock, par value $0.0001 per share | 2,412 | $7.91 footnote F2 | $19K | |
| ||||||
| John Kenneth Jenkins | Open-market sale | Common Stock, par value $0.0001 per share | 4,800 | $7.91 footnote F2 | $38K | |
| ||||||
| Nishant C. Saxena - Officer | Open-market purchase | Common Stock, par value $0.0001 per share | 4,500 | $7.33 footnote F1 | $33K | |
| Nishant C. Saxena - Officer | Open-market purchase | Common Stock, par value $0.0001 per share | 9,000 | $7.58 | $68K | |
| ||||||
| Nishant C. Saxena - Officer | Grant or award | Stock options (right to buy) | 192,300 | $0.00 | - | |
| Nishant C. Saxena - Officer | Grant or award | Common Stock, par value $0.0001 per share | 58,300 footnote F1 | $0.00 | - | |
| ||||||
| Winston Kung | Grant or award | Common Stock, par value $0.0001 per share | 3,800 footnote F1 | $0.00 | - | |
| Winston Kung | Grant or award | Stock options (right to buy) | 12,300 | $0.00 | - | |
| ||||||
| Rachelle Suzanne Jacques | Grant or award | Common Stock, par value $0.0001 per share | 3,800 footnote F1 | $0.00 | - | |
| Rachelle Suzanne Jacques | Grant or award | Stock options (right to buy) | 12,300 | $0.00 | - | |
| ||||||
| John Kenneth Jenkins | Grant or award | Common Stock, par value $0.0001 per share | 3,800 footnote F1 | $0.00 | - | |
| John Kenneth Jenkins | Grant or award | Stock options (right to buy) | 12,300 | $0.00 | - | |
| ||||||
| Anne Altmeyer | Grant or award | Common Stock, par value $0.0001 per share | 3,800 footnote F1 | $0.00 | - | |
| Anne Altmeyer | Grant or award | Stock options (right to buy) | 12,300 | $0.00 | - | |
| ||||||
| Yong Ben | Grant or award | Common Stock, par value $0.0001 per share | 3,800 footnote F1 | $0.00 | - | |
| Yong Ben | Grant or award | Stock options (right to buy) | 12,300 | $0.00 | - | |
| ||||||
| Brent Pfeiffenberger | Grant or award | Common Stock, par value $0.0001 per share | 7,500 footnote F1 | $0.00 | - | |
| Brent Pfeiffenberger | Grant or award | Stock options (right to buy) | 24,700 | $0.00 | - | |
| ||||||
| Dominic Smethurst - Officer | Open-market sale | Common Stock, par value $0.0001 per share | 6,097 | $8.30 footnote F2 | $51K | |
| ||||||
| Ian Hodgson - Officer | Open-market sale | Common Stock, par value $0.0001 per share | 847 | $7.38 footnote F2 | $6K | |
| ||||||
| Sean F. Moran - Officer | Open-market sale | Common Stock, par value $0.0001 per share | 4,701 | $7.78 footnote F2 | $37K | |
| ||||||
| Yuval Cohen - Officer | Open-market sale | Common Stock, par value $0.0001 per share | 13,871 | $7.78 footnote F2 | $108K | |
| ||||||
| Dominic Smethurst - Officer | Open-market sale | Common Stock, par value $0.0001 per share | 3,285 | $8.09 footnote F2 | $27K | |
| ||||||
| Ian Hodgson - Officer | Open-market sale | Common Stock, par value $0.0001 per share | 2,415 | $8.09 footnote F2 | $20K | |
| ||||||
| Dominic Smethurst - Officer | Grant or award | Common Stock, par value $0.0001 per share | 28,365 footnote F1 | $0.00 | - | |
| Dominic Smethurst - Officer | Grant or award | Stock options (right to buy) | 85,095 | $0.00 | - | |
| ||||||
| Sean F. Moran - Officer | Grant or award | Common Stock, par value $0.0001 per share | 28,082 footnote F1 | $0.00 | - | |
| Sean F. Moran - Officer | Grant or award | Stock options (right to buy) | 84,247 | $0.00 | - | |
| ||||||
| Yuval Cohen - Officer | Grant or award | Common Stock, par value $0.0001 per share | 50,000 footnote F1 | $0.00 | - | |
| Yuval Cohen - Officer | Grant or award | Stock options (right to buy) | 150,000 | $0.00 | - | |
| ||||||
| Ian Hodgson - Officer | Grant or award | Common Stock, par value $0.0001 per share | 28,365 footnote F1 | $0.00 | - | |
| Ian Hodgson - Officer | Grant or award | Stock options (right to buy) | 85,095 | $0.00 | - | |
| ||||||
| Yuval Cohen - Officer | Option exercise | Stock options (right to buy) | 8,973 | $0.00 | - | |
| Yuval Cohen - Officer | Option exercise | Common Stock, par value $0.0001 per share | 18,660 | $4.26 | $79K | |
| Yuval Cohen - Officer | Open-market sale | Common Stock, par value $0.0001 per share | 18,660 | $17.01 footnote F3 | $317K | |
| Yuval Cohen - Officer | Option exercise | Common Stock, par value $0.0001 per share | 8,973 | $4.26 | $38K | |
| Yuval Cohen - Officer | Open-market sale | Common Stock, par value $0.0001 per share | 8,973 | $17.14 footnote F4 | $154K | |
| Yuval Cohen - Officer | Option exercise | Stock options (right to buy) | 18,660 | $0.00 | - | |
| ||||||
| Sean F. Moran - Officer | Option exercise | Common Stock, par value $0.0001 per share | 12,981 | $4.26 | $55K | |
| Sean F. Moran - Officer | Open-market sale | Common Stock, par value $0.0001 per share | 12,981 | $17.02 footnote F3 | $221K | |
| Sean F. Moran - Officer | Option exercise | Stock options (right to buy) | 12,981 | $0.00 | - | |
| ||||||
| Anne Altmeyer | Option exercise | Common Stock, par value $0.0001 per share | 1,060 | $4.80 | $5K | |
| Anne Altmeyer | Open-market sale | Common Stock, par value $0.0001 per share | 1,060 | $20.50 | $22K | |
| Anne Altmeyer | Option exercise | Stock options (right to buy) | 1,060 | $0.00 | - | |
Item 7.01, 8.01, 9.01
Item 2.02, 7.01, 9.01
Item 1.01, 7.01, 9.01
Item 7.01, 8.01, 9.01
Recent CRBP Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Stifel, Nicolaus & Company, Inc CIAS /FA | Officer | 17,000 | $171K | View on EDGAR | |
| Stifel, Nicolaus & Company, Inc CIAS /FA | Officer | 12,000 |
CRBP insider trading FAQ
What is the latest insider trade for CRBP?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) had 5 insider filings in the last 90 days, with the most recent on 2026-09-15. The full record for CRBP runs to 29 Form 4 filings, the earliest from 2025-10-21. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying CRBP stock?
1 insider purchase of CRBP was filed in the last 90 days, totaling $25K.
How many insiders are selling CRBP stock?
3 insider sales of CRBP were filed in the last 90 days, totaling $308K.
Where can I see CRBP SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects CRBP Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Yong Ben view on EDGAR
- - Leonardo Viana Nicacio view on EDGAR
- - Nishant C. Saxena view on EDGAR
- - Yuval Cohen view on EDGAR
- - Sean F. Moran view on EDGAR
- - Winston Kung view on EDGAR
- - Anne Altmeyer view on EDGAR
- - John Kenneth Jenkins view on EDGAR
- - Nishant C. Saxena view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where CRBP's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow CRBP with a 7-day demo
- CRBP on your watchlist
- Every CRBP Form 4 filing on record
- Up to 3 months of CRBP price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
